Skip to content
Screener

Altimmune ALT Q3 2026 earnings

Reported November 12, 2026 · Before market open

EPS-$0.15Miss by $0.02
Revenue estimate$1.8K
EPS estimate-$0.13
“We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide. Our global PERFORMA Phase 3 trial in MASH is ramping up, and we are very encouraged by the progress to date and the enthusiasm we see from the MASH community. In AUD, we look forward to engaging with the FDA in an End-of-Phase 2 meeting where we will leverage our strong RECLAIM data to discuss a Phase 3 registrational program. Following the recent AASLD meeting, our conviction in pemvidutide's potential is stronger than ever, as we focus on delivering meaningful benefit to patients with serious liver diseases.”
Jerry Durso

Next report

Date not yet announced

FAQ

When did Altimmune report Q3 2026 earnings?
Altimmune (ALT) reported Q3 2026 earnings on November 12, 2026 before market open.
What were Altimmune's Q3 2026 revenue and EPS?
Altimmune reported eps of $-0.15 for Q3 2026.
Did Altimmune beat estimates in Q3 2026?
EPS missed the consensus estimate of $-0.13 by $0.02.
How did Altimmune's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 28.6% from $-0.21.
Where can I find Altimmune's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001326190-26-000067) and the 10-Q periodic report (0001326190-26-000070) directly on SEC EDGAR. The filing index links above go to sec.gov.